



TSIBD 2019 WINTER FORUM

23 February 2019, Saturday (Taipei, Sheraton Hotel)

Time: 10:00 am – 16:00 pm Venue: 臺北喜來登 2 樓瑞穗廳

Time	Topic	Speaker	Moderator
10:00 – 10:15	Registration		
10:15 – 10:20	Opening	王正一教授	
10:30 – 11:00	Treatment Goal in IBD – Role of Conventional therapy vs Biologics	董建志 醫師	倪衍玄 教授
11:00 – 11:30	Pre- and postoperative management of Crohn's Disease	周仁偉 主任	謝銘鈞 教授
11:30 – 12:00	Acute Severe UC Management and Emerging Evidence of Therapy	張崇信 醫師	許秉毅 教授
12:00 – 12:30	TSIBD Registry Update	魏淑鈺 副教授	翁昭旻 教授
12:30 – 13:30	Lunch		
13:30 – 14:00	Role of Endoscopic Therapy in IBD: Stricture, Dysplasia	黃天祐 醫師	王鴻源 教授
14:00 – 14:30	Fistula Management in Crohn's disease patients – Surgeon's perspective	林春吉 醫師	王照元 教授
14:30 – 14:45	Break		
14:45 – 15:15	Updates on Treatment of IBD patients with Active infection and Malignancy	戴維震 醫師	吳登強 副院長
15:15 – 15:45	Role of Sonography in IBD Management	李熹昌 醫師	陳冠仰 副院長
15:45 – 16:00	Closing	翁昭旻 教授	

董建志 醫師 (Chien-Chih Tung, M.D., M.S.)



Education:

1996-2003: College of Medicine, China Medical University, Taichung, Taiwan

2013-2017: Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Specialty:

Internal Medicine, Gastroenterology & Hepatology, Endoscopy, Sonography

Training and Experiences:

2005~2008: Resident training, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

2008~2010: Fellowship and chief residency, Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

2010~2012: Attending physician, Division of Gastroenterology, Department of Internal Medicine, New Taipei City Hospital, New Taipei, Taiwan

2012~2013: Attending physician, Division of Gastroenterology, Department of Internal Medicine, West Garden Hospital, Taipei, Taiwan

2013~ Attending physician, Department of Integrated Diagnostics & Therapeutics, National Taiwan University Hospital, Taipei, Taiwan

Publication:

1. A nationwide population-based study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan.

Wei SC, Lin MH, Tung CC, Weng MT, Kuo JS, Shieh MJ, Wang CY, Ho WC, Wong JM, Chen PC. BMC Gastroenterol. 2013 Dec 6;13:166. doi: 10.1186/1471-230X-13-166.

2. Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn's disease.

Tung CC, Wong JM, Lee WC, Liu HH, Chang CH, Chang MC, Chang YT, Shieh MJ, Wang CY, Wei SC. J Gastroenterol Hepatol. 2014 Apr;29(4):723-9.

3. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.

Lin WC, Wong JM, Tung CC, Lin CP, Chou JW, Wang HY, Shieh MJ, Chang CH, Liu HH, Wei SC; Taiwan Society of Inflammatory Bowel Disease Multicenter Study. World J Gastroenterol. 2015 Dec 28;21(48):13566-73. doi: 10.3748/wjg.v21.i48.13566.

4. Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study.

Weng MT, Tung CC, Lee YS, Leong YL, Shieh MJ, Shun CT, Wang CY, Wong JM, Wei SC. BMC Gastroenterol. 2017 Feb 13;17(1):28. doi: 10.1186/s12876-017-0586-9.

5. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.

Wei SC, Tung CC, Weng MT, Wong JM. Intest Res. 2018 Oct;16(4):546-553. doi: 10.5217/ir.2018.00052. Epub 2018 Oct 1